SYNTHIA at AD/PD™ 2026 – Advancing Synthetic Data Innovation for Neurodegenerative Disease Research
We are pleased to announce that SYNTHIA will participate in the upcoming AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, taking place from 17–21 March 2026 in Copenhagen, Denmark, and online.
Gates Ventures will represent SYNTHIA to share more about our Alzheimer’s use case, and how synthetic data can support research into neurodegenerative diseases through privacy-preserving and scientifically robust approaches.
Within SYNTHIA, this work explores how synthetic data can help advance Alzheimer’s disease research by supporting the development of predictive models, enabling responsible use of sensitive health data, and creating new opportunities for safer experimentation. By generating realistic synthetic datasets, SYNTHIA aims to contribute to early detection research, personalized care approaches, and trustworthy AI development in this important field.
The AD/PD™ International Conference on Alzheimer’s and Parkinson’s Diseases is one of the leading global events for neurodegenerative disease research and innovation. The annual scientific meeting brings together international experts in neurology, neuroscience, translational medicine, and clinical research to discuss the latest advances in Alzheimer’s disease, Parkinson’s disease, and related neurological disorders. A defining strength of the conference is its focus on shared disease mechanisms and interdisciplinary exchange across scientific and clinical domains.
This year’s conference will once again provide an important platform for connecting researchers, clinicians, and innovators working toward better outcomes for people affected by neurodegenerative diseases.
This aligns closely with SYNTHIA’s mission to accelerate responsible health innovation through trustworthy synthetic data generation.
